Subscribe To
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T efforts Advancing TCR-T Library Program towards Phase 2 readiness with accelerated patient enrollment following proof-of-concept of Sleeping Beauty TCR-T in solid tumors targeting driver mutations Expanded TCR library with two new TCRs; […] The post Alaunos Therapeutics Reports Fourth Quarter and Full Year 2...
Read More
Posted: Mar 7 2023, 12:00
Author Name: forextv
Views: 082176